INSIGHTS ON CLINICAL TRIAL DESIGN
-
![Why Specialty Lab Samples Are So Vulnerable To Trial Execution Errors]( "Why Specialty Lab Samples Are So Vulnerable To Trial Execution Errors")
Why Specialty Lab Samples Are So Vulnerable To Trial Execution ErrorsBiomarkers and other specialty lab samples are among the most fragile parts of clinical trial execution, but what makes them so vulnerable to mishandling, and what are the effects?
-
![mobile-app-clinical-trials-GettyImages-1321691686]( "Rare Disease Development: Navigating Small Populations And Complex Protocols")
Rare Disease Development: Navigating Small Populations And Complex ProtocolsLearn how you can navigate the complexity of rare disease development with flexible trial design, integrated regulatory strategy, and data-driven execution built for small populations and global programs.
-
![Digital Data Collection]( "Modernizing Clinical Research With Patient-Centric Digital Data Collection")
Modernizing Clinical Research With Patient-Centric Digital Data CollectionAccelerate clinical trial modernization with streamlined collection of continuous, high-precision data centered on the patient.
-
![DNA molecule-GettyImages-2148124383]( "5 Key Considerations For Choosing The Right ERP")
5 Key Considerations For Choosing The Right ERPSelecting an Enterprise Resource Planning (ERP) system is a pivotal decision for life sciences organizations, influencing regulatory compliance, operational efficiency, and long-term growth.
-
Ophthalmology Patient Engagement And Retention: Point-Of-Need Execution4/6/2026
Dropout in retinal trials is often a logistical failure. Reducing travel burden and bringing specialized care to the patient can slash attrition rates and secure critical trial timelines.
-
Partnership Driving Superior Enrollment And Speed In Phase III Trial1/31/2025
Examine the partnership between CRIO and Sitero, including how it underscores the significant impact of technology in optimizing trial performance and accelerating treatment development.
-
Illuminating IHC: From Biomarker To Clinical Trial Assay5/2/2025
Through this presentation, Immunohistochemistry (IHC) expert equip you with the knowledge needed to effectively utilize IHC in your research and clinical practice.
-
The Story Behind MIDBA: An Exclusive Interview8/20/2026
A new regulatory framework reduces PK bridging study needs, helping sponsors streamline device transitions, lower costs, speed up timelines, and boost regulatory predictability for combination products.
-
Strategic Implications Of The Single Phase 3 Approval Paradigm7/21/2026
As FDA single-trial approvals gain traction, CNS developers need stronger early evidence. Learn how biomarkers, patient selection, and regulatory strategy can accelerate development.
CLINICAL TRIAL DESIGN SOLUTIONS
-
![GettyImages-1819626829 patient recruitment]( "Accelerating Patient Recruitment In Oncology Since 2005")
CSSi is a global, full-service company offering customized services to support recruitment and retention programs around the world.
-
![getty-1311598658-data-analytics]( "Optimize And Expedite Clinical Trial Design, Planning, and Execution")
Obtain smarter, faster, and more resilient clinical trials that reduce cost, improve outcomes, and bring life-changing therapies to patients sooner with integrated, user-friendly technology.
-
![GettyImages-2160908575-patient-care-nurse]( "The Problem-Solving, Patient Advocate Team That Every Trial Needs")
Patient Kindness is a supplemental layer of premium support that offers a more seamless clinical trial experience for patients and caregivers with more complex or nuanced needs.
-
![GettyImages-2167387195-computer-graphs-hand-team-digital]( "De-Risk Randomization With The Endpoint Biostatistical Approach")
With over 15 years of RTSM experience, high-touch quality management, and forward-thinking technology, our solutions enhance trial speed, accuracy, and operational efficiency.
-
![Mother abd adult daughter at doctors-GettyImages-2213748134]( "Solutions For Patients Across Most Therapeutic Areas And Indications")
Struggling with slow recruitment or fragmented sites? Explore how 35 coordinated sites and 3.5M+ patients can streamline trials from startup to close.
